scholarly journals Ragweed Pollen Allergy: Burden, Characteristics, and Management of an Imported Allergen Source in Europe

2018 ◽  
Vol 176 (3-4) ◽  
pp. 163-180 ◽  
Author(s):  
Kuan-Wei Chen ◽  
Laura Marusciac ◽  
Paul Tudor Tamas ◽  
Rudolf Valenta ◽  
Carmen Panaitescu
1981 ◽  
pp. 175-177
Author(s):  
F. Horak ◽  
S. Jäger ◽  
R. Türk

2019 ◽  
Vol 7 (2) ◽  
pp. 86-87
Author(s):  
Claudia Traidl-Hoffmann

Ambrosia artemisiifolia, also known as common or short ragweed, is an invasive annual flowering herbaceous plant that has its origin in North America. Nowadays, ragweed can be found in many areas worldwide. Ragweed pollen is known for its high potential to cause type I allergic reactions in late summer and autumn and represents a major health problem in America and several countries in Europe. Climate change and urbanization, as well as long distance transport capacity, enhance the spread of ragweed pollen. Therefore ragweed is becoming domestic in non-invaded areas which in turn will increase the sensitization rate. So far 11 ragweed allergens have been described and, according to IgE reactivity, Amb a 1 and Amb a 11 seem to be major allergens. Sensitization rates of the other allergens vary between 10 and 50%. Most of the allergens have already been recombinantly produced, but most of them have not been characterized regarding their allergenic activity, therefore no conclusion on the clinical relevance of all the allergens can be made, which is important and necessary for an accurate diagnosis. Pharmacotherapy is the most common treatment for ragweed pollen allergy but fails to impact on the course of allergy. Allergen-specific immunotherapy (AIT) is the only causative and disease-modifying treatment of allergy with long-lasting effects, but currently it is based on the administration of ragweed pollen extract or Amb a 1 only. In order to improve ragweed pollen AIT, new strategies are required with higher efficacy and safety.


Author(s):  
O.P. Ukhanova ◽  
I.I. Ebzeeva

Сезонный аллергический ринит и конъюнктивит, вызванные пыльцой амброзии полыннолистной на Юге России, являются одной из частых причин обращаемости пациентов за медицинской помощью в период с августа по сентябрь. Появление нового препарата Рагвизакс осенью 2019 г. для проведения сублингвальной аллерген-специфической иммунотерапии (слАСИТ) оптимизирует возможности оказания качественной медицинской помощи пациентам с амброзийным поллинозом. Известно, что АСИТ является основной терапией, модифицирующей течение поллиноза. Удобство применения, высокий профиль безопасности и эффективности слАСИТ позволят увеличить приверженность врачей-аллергологов и пациентов к лечению.Seasonal allergic rhinitis and conjunctivitis, caused by ragweed pollen in the south of Russia, are the most common reasons to take medical advice for sensitized patients from August to September. Sublingual immunotherapy (slASIT) using ragweed sublingual tablet Ragvizax , which was registered in Russia in 2019 provides qualified medical care for patients with ragweed pollen allergy. It is known that ASIT is the basic therapy, that modifies pollen allergy progression. Easy to use, high safety and efficacy profile of slASIT with Ragvizax will help to improve allergists and patients compliance.


2011 ◽  
Vol 127 (2) ◽  
pp. AB170-AB170 ◽  
Author(s):  
W. Hemmer ◽  
U. Schauer ◽  
A. Trinca ◽  
C. Neumann ◽  
R. Jarisch

2021 ◽  
Vol 21 (5) ◽  
Author(s):  
Laura Haidar ◽  
Tudor-Paul Tamas ◽  
Frank Stolz ◽  
Raul Florian Petrisor Patrascu ◽  
Kuan-Wei Chen ◽  
...  

2018 ◽  
Vol 6 (4) ◽  
pp. 206-207
Author(s):  
Claudia Traidl-Hoffmann

Ambrosia artemisiifolia, also known as common or short ragweed, is an invasive annual flowering herbaceous plant that has its origin in North America. Nowadays, ragweed can be found in many areas worldwide. Ragweed pollen is known for its high potential to cause type I allergic reactions in late summer and autumn and represents a major health problem in America and several countries in Europe. Climate change and urbanization, as well as long distance transport capacity, enhance the spread of ragweed pollen. Therefore ragweed is becoming domestic in non-invaded areas which in turn will increase the sensitization rate. So far 11 ragweed allergens have been described and, according to IgE reactivity, Amb a 1 and Amb a 11 seem to be major allergens. Sensitization rates of the other allergens vary between 10 and 50%. Most of the allergens have already been recombinantly produced, but most of them have not been characterized regarding their allergenic activity, therefore no conclusion on the clinical relevance of all the allergens can be made, which is important and necessary for an accurate diagnosis. Pharmacotherapy is the most common treatment for ragweed pollen allergy but fails to impact on the course of allergy. Allergen-specific immunotherapy (AIT) is the only causative and disease-modifying treatment of allergy with long-lasting effects, but currently it is based on the administration of ragweed pollen extract or Amb a 1 only. In order to improve ragweed pollen AIT, new strategies are required with higher efficacy and safety.


2018 ◽  
Vol 25 (2) ◽  
pp. 307-313
Author(s):  
Krisztina Vörös ◽  
János Bobvos ◽  
János Mihály Varró ◽  
Tibor Málnási ◽  
Tamás Kói ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document